Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.21.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
REVENUES    
Total revenues $ 1,899,496 $ 1,456,755
EXPENSES    
Cost of product sales 1,202,479 991,651
General and administrative 2,873,939 918,379
Research and development 3,499,373 238,059
Sales and marketing 136,587 92,262
Total expenses 7,712,378 2,240,351
LOSS FROM OPERATIONS (5,812,882) (783,596)
OTHER (INCOME) EXPENSE, NET    
Gain on change in fair value of warrant liabilities (2,122,900)
Interest (income) expense, net (17,343) 90,757
Other income, net (542) (1,158)
Total other (income) expense, net (2,140,785) 89,599
LOSS BEFORE PROVISION FOR INCOME TAXES (3,672,097) (873,195)
PROVISION FOR INCOME TAXES 530 (619)
NET LOSS $ (3,672,627) $ (872,576)
Net loss per common share, basic and diluted $ (0.13) $ (0.16)
Weighted-average number of shares outstanding, basic and diluted 28,165,796 5,602,214
Net Product Sales [Member]    
REVENUES    
Total revenues $ 1,420,842 $ 1,411,755
License Revenue [Member]    
REVENUES    
Total revenues 478,654
Collaborative Research Revenue [Member]    
REVENUES    
Total revenues $ 45,000